This study aims to fill that gap by providing real-world OS estimates and examining how demographic, clinicopathological, and treatment factors affect OS in patients with de novo metastatic HER2-positive breast cancer, using a large sample from the National Cancer Database (NCDB). This evidence concerns the gene ERBB2 and breast carcinoma.